NO951000L - Fremgangsmåte for reduksjon av blodnivåer av totalt kolesterol og lavdensitets lipoprotein-kolesterol - Google Patents

Fremgangsmåte for reduksjon av blodnivåer av totalt kolesterol og lavdensitets lipoprotein-kolesterol

Info

Publication number
NO951000L
NO951000L NO951000A NO951000A NO951000L NO 951000 L NO951000 L NO 951000L NO 951000 A NO951000 A NO 951000A NO 951000 A NO951000 A NO 951000A NO 951000 L NO951000 L NO 951000L
Authority
NO
Norway
Prior art keywords
cholesterol
density lipoprotein
low density
total blood
reducing total
Prior art date
Application number
NO951000A
Other languages
English (en)
Norwegian (no)
Other versions
NO951000D0 (no
Inventor
Steven L Nissen
Original Assignee
Univ Iowa State Res Found Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25484425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO951000(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Iowa State Res Found Inc filed Critical Univ Iowa State Res Found Inc
Publication of NO951000D0 publication Critical patent/NO951000D0/no
Publication of NO951000L publication Critical patent/NO951000L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO951000A 1992-09-16 1995-03-15 Fremgangsmåte for reduksjon av blodnivåer av totalt kolesterol og lavdensitets lipoprotein-kolesterol NO951000L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94640492A 1992-09-16 1992-09-16
PCT/US1993/008695 WO1994006417A1 (en) 1992-09-16 1993-09-15 Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol

Publications (2)

Publication Number Publication Date
NO951000D0 NO951000D0 (no) 1995-03-15
NO951000L true NO951000L (no) 1995-03-15

Family

ID=25484425

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951000A NO951000L (no) 1992-09-16 1995-03-15 Fremgangsmåte for reduksjon av blodnivåer av totalt kolesterol og lavdensitets lipoprotein-kolesterol

Country Status (12)

Country Link
US (1) US5360613A (da)
EP (1) EP0660706B1 (da)
JP (1) JP3148243B2 (da)
AU (1) AU673002B2 (da)
BR (1) BR9307035A (da)
CA (1) CA2142314C (da)
DE (1) DE69327468T2 (da)
ES (1) ES2142353T3 (da)
FI (1) FI951218A7 (da)
NO (1) NO951000L (da)
NZ (1) NZ256300A (da)
WO (1) WO1994006417A1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
US5716926A (en) * 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
US6103764A (en) * 1997-11-07 2000-08-15 Iowa State University Research Foundation, Inc. Method for increasing the aerobic capacity of muscle
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
WO2000043017A1 (en) * 1999-01-21 2000-07-27 Steroidogenesis Inhibitors International Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human
WO2002094255A1 (de) * 2001-05-18 2002-11-28 Lonza Ag Verfahren zur herstellung fester formulierungen von natrium-3-hydroxy-3-methylbutyrat
US20040048925A1 (en) * 2002-09-09 2004-03-11 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) * 2002-09-17 2004-06-03 Dobbins Thomas A Compositions for the parenteral administration of calcium and magnesium
US6812249B2 (en) * 2003-03-04 2004-11-02 Sal Abraham Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use
WO2005096846A1 (en) * 2004-03-11 2005-10-20 Wiley Organics, Inc. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
WO2007056176A2 (en) * 2005-11-03 2007-05-18 Southwest Immunology, Inc. Compositions for preventing and reducing delayed onset muscle soreness
WO2007075605A2 (en) 2005-12-19 2007-07-05 Abbott Laboratories Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type and type 2 cytokine production
US20080200422A1 (en) * 2007-01-09 2008-08-21 Cavener Douglas R Methods for reduction of adipose tissue mass
PT2381784T (pt) * 2008-12-09 2018-10-30 Metabolic Tech Inc Intervenção nutricional para melhorar função e força muscular
US9770424B2 (en) 2008-12-09 2017-09-26 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9259430B2 (en) 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9707241B2 (en) 2008-12-09 2017-07-18 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9539224B2 (en) 2008-12-09 2017-01-10 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11173167B2 (en) 2008-12-09 2021-11-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11042605B2 (en) 2009-07-21 2021-06-22 Ccqcc Corp. Method and apparatus for calibration and testing of scientific measurement equipment
US8538727B2 (en) * 2009-07-21 2013-09-17 George S. Cembrowski Method and apparatus for calibration and testing of scientific measurement equipment
SG182808A1 (en) 2010-01-29 2012-09-27 Abbott Lab Aseptically packaged nutritional liquids comprising hmb
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
MX2012008785A (es) 2010-01-29 2012-08-17 Abbott Lab Emulsiones nutricionales que comprenden beta-hidroxi-beta-metilbut irato (hmb) de calcio.
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
EP3466418A1 (en) * 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
BR112014003434A2 (pt) * 2011-08-15 2017-03-01 Abbott Lab processo para produção de hmb e seus sais
WO2013067485A1 (en) 2011-11-03 2013-05-10 University Of Florida Research Foundation, Inc. Nutritional supplement for weight management
WO2012140276A2 (en) * 2011-11-17 2012-10-18 Lonza Ltd Process for the preparation of 3-hydroxy-3-methylbutyric acid or its calcium salts
WO2014040067A1 (en) 2012-09-10 2014-03-13 Metabolic Technologies, Inc. Composition of hmb and atp and methods of use
EP3122348B1 (en) 2014-03-27 2020-05-27 Winterfield, Roland, W. Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
US12208073B2 (en) 2015-09-16 2025-01-28 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
JP7114458B2 (ja) 2015-09-16 2022-08-08 メタボリック・テクノロジーズ，インコーポレーテッド 軟組織外傷からの回復を増強するためのβ－ヒドロキシ－β－メチルブチレート（ＨＭＢ）の組成物および使用方法
KR20180088809A (ko) 2015-11-19 2018-08-07 가부시키가이샤 오츠카 세이야쿠 코죠 3-히드록시이소발레르산의 1가 양이온염의 결정 및 그 결정의 제조 방법
BR112018014920A2 (en) 2016-01-21 2018-12-18 Metabolic Technologies, Inc. methods of modulating autophagy, treating or reducing the likelihood of onset of an autophagy-mediated condition, treating, inhibiting, reducing, decreasing, or preventing an age-related disorder, modulating the expression or activity of at least one factor transcription, treatment, prevention, reduction, inhibition or reduction of a pathological condition attributable to a state of nutrient excess, promoting longevity by modulating autophagy, increasing the length of time a mammal can lead a lifestyle active without suffering from conditions associated with aging and extending the health of a mammal.
EP3476825A4 (en) 2016-06-24 2020-02-26 Kyowa Hakko Bio Co., Ltd. CRYSTAL OF BETA-HYDROXY-BETA-METHYLBUTTERIC ACID-AMINO ACID SALT AND PRODUCTION METHOD THEREFOR
PL3528801T3 (pl) 2016-10-21 2025-02-03 Metabolic Technologies, LLC Kompozycje i sposoby zastosowania beta-hydroksy-beta-metylomaślanu (hmb) i probiotyków

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629449A (en) * 1968-04-22 1971-12-21 Majid Siddiqi Process of combatting hypercholesterolemia
US4760090A (en) * 1986-03-11 1988-07-26 Iowa State University Research Foundation, Inc. Method of feeding ketoisocaproate to cattle and sheep
US4764531A (en) * 1986-03-11 1988-08-16 Iowa State University Research Foundation, Inc. Method of feeding ketoisocaproate to laying chickens
US5087472A (en) * 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US4992470A (en) * 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals

Also Published As

Publication number Publication date
FI951218L (fi) 1995-03-15
EP0660706B1 (en) 1999-12-29
JPH08501777A (ja) 1996-02-27
FI951218A0 (fi) 1995-03-15
US5360613A (en) 1994-11-01
AU673002B2 (en) 1996-10-24
CA2142314A1 (en) 1994-03-31
WO1994006417A1 (en) 1994-03-31
NO951000D0 (no) 1995-03-15
BR9307035A (pt) 1999-06-29
DE69327468D1 (de) 2000-02-03
NZ256300A (en) 1997-06-24
FI951218A7 (fi) 1995-03-15
DE69327468T2 (de) 2000-05-11
CA2142314C (en) 1999-06-01
EP0660706A4 (da) 1995-07-26
EP0660706A1 (en) 1995-07-05
AU4922593A (en) 1994-04-12
ES2142353T3 (es) 2000-04-16
JP3148243B2 (ja) 2001-03-19

Similar Documents

Publication Publication Date Title
CA2142314A1 (en) Method of Reducing Blood Levels of Total Cholesterol and Low-Density Lipoprotein Cholesterol
Chao et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease
Mavor et al. The iliofemoral venous segment as a source of pulmonary emboli
CA2238098A1 (en) Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis
ATE79544T1 (de) Zusammensetzungen zur behandlung von hypercholesterinaemie.
CA2129541A1 (en) Method of Promoting Nitrogen Retention in Humans
CA2285203A1 (en) Compositions containing capsaicin or capsaicin analogues and a local anesthetic
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
NO950518L (no) Anvendelse av terpenforbindelser for redusert frigjöring av arachidonsyre og bestemmelsesmediatorer
RU95113499A (ru) Способ повышения мочеотделения у человека, способ снижения уровней холестерина и липопротеинов низкой плотности, применение (+) доксазозина
KR910005858A (ko) 지방산 요법
GB2210789A (en) Topical application for skin care
Verbov Cutaneous polyarteritis nodosa in a young child.
ATE145825T1 (de) Behandlung von erhöhtem blutdruck
KR940013503A (ko) 동맥경화증의 예방 또는 치료용 약제학적 조성물
US6264646B1 (en) Method for preventing and reversing atherosclerosis in mammals
AU2431984A (en) Shampoo Composition of Neostigmine or Pyridostigmine
Espinoza Antiphospholipid antibody syndrome: treatment
ES2087764T3 (es) Uso del ajo de oso en el tratamiento o prevencion de los trastornos circulatorios.
US4150119A (en) Method for treatment of vascular disease
Blanco et al. Safe use of ursodeoxycholic acid in the treatment of dyspeptic symptoms in patients with chronic active hepatitis: a double-blind controlled trial
Bes Nicardipine in the prevention of migraine headaches
KOPJAS Folic acid for the treatment of chronic leg ulcers in elderly patients

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application